Management & Regulatory

The UK has taken a monumental step in the fight against extensive-stage small cell lung cancer (SCLC) with the recent approval of Hetronifly. This approval by the Medicines and Healthcare products Regulatory Agency (MHRA) introduces Hetronifly as the first anti-PD-1 monoclonal antibody available in

Faced with the debilitating impacts of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder characterized by muscle weakness, sensory loss, and pain, new treatment options become critical. Vyvgart SC Injection offers a promising solution for those affected by this

In the world of oncology, advancements in treatment options often mark pivotal moments in patient care. Ivan Kairatov, a biopharma expert with profound knowledge in tech and innovation, shares insights into the nuanced landscape of smouldering multiple myeloma (SMM) and its treatment. With his

Recent developments in the United Kingdom's medical regulatory sphere have stirred significant discourse among healthcare professionals, primarily focusing on the need for an exclusive regulatory framework for doctors. The British Medical Association (BMA) has been vocal about the necessity of

The US FDA's accelerated approval of Datroway (datopotamab deruxtecan) marks a notable advancement in the realm of lung cancer therapy. This approval is groundbreaking, as Datroway is the first TROP2-directed therapy sanctioned for lung cancer in the United States, specifically targeting a

In recent developments, Dupixent, co-developed by Sanofi and Regeneron, has emerged as a promising solution for individuals suffering from bullous pemphigoid (BP), a debilitating skin disorder predominantly impacting older adults. This drug's approval is seen as a groundbreaking advancement by